公司财报发布相关 - 公司将于2024年8月14日周三美国东部时间下午4:30股市收盘后召开财报会议[1] - 公司名为SHF Holdings Inc. 以Safe Harbor Financial运营在纳斯达克上市代码为SHFS将公布2024年第二季度截至6月30日的财报[2] - 公司首席执行官Sundie Seefried和首席财务官Jim Dennedy将主持会议并进行网络直播讨论财报并提供业务亮点[3] 会议参与方式 - 若要收听会议可拨打电话646 - 307 - 1963或800 - 715 - 9871(免费)密码为9502925也可通过https://edge.media - server.com/mmc/p/d2eee4n4观看直播或重播[5] 公司概况 - 公司是为受监管大麻行业提供金融服务和信贷设施的领导者[2] - 公司是首批为金融机构提供合规监控和验证服务的服务提供商为大麻等相关运营商提供传统银行服务在过去八年为41个州及美国地区的企业促成超过230亿美元的存款交易[6]

IRVING, Texas, July 31, 2024 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR), the world's leading company turning food waste into sustainable products and producer of renewable energy, today announced that its 50/50 joint venture Diamond Green Diesel (DGD) will provide the first regular supply of neat sustainable aviation fuel (SAF), to be blended with conventional jet fuel to create blended SAF, for commercial air travel out of John F. Kennedy International Airport (JFK) to begin in the next few month ...

ATHENS, Greece, July 31, 2024 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the "Company"), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today reported a net loss of $2.8 million and a net loss attributed to common stockholders of $4.2 million for the second quarter of 2024. This compares to net income of $10.4 million and net income attributed to common stockholders of $8.9 million for the second quarter of 2023. Loss per share for the second ...

文章核心观点 - 美国FDA授予公司的VCN-01用于治疗视网膜母细胞瘤的罕见儿童药物指定[1][2][3] - VCN-01是一种全身性的选择性肿瘤溶解腺病毒,可以多方面抑制肿瘤生长[5] - 公司正在与医生和监管机构密切合作,优化VCN-01在儿童晚期视网膜母细胞瘤中的临床开发策略[2] - 最近一项针对复发性视网膜母细胞瘤的I期临床试验结果显示积极[2] 行业概况 - 视网膜母细胞瘤是儿童最常见的眼部肿瘤,每年在美国约有200-300例新发病例[4] - 保存生命和避免失明等严重后果仍然是一大挑战[4] - 在资源匮乏的国家,儿童视网膜母细胞瘤患者更容易失去眼睛并死于转移性疾病[4] 公司概况 - 公司是一家多元化的临床阶段生物制药公司,专注于开发治疗癌症和相关疾病的新药[6][7] - 公司的主要产品包括VCN-01、SYN-004和SYN-020,涉及多种适应症[6][7] - 如果VCN-01获批上市,公司可能有资格获得优先审评券[3] - 公司目前现金储备可提供到2025年第一季度的运营资金[8]

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment, alone and in combination with lecanemab, protected cultures of primary neurons from the toxic effects of amyloid-β BOTHELL, Wash., July 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow n ...

WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of plain language summaries of results from two clinical trials on XPHOZAH® (tenapanor), NORMALIZE and OPTIMIZE, in Current Medical Research and Opinion. The plain language summaries were developed by the authors to help adult pati ...

Delivers 15.0% Unit Growth Domestic Same Store Sales Increased 28.7%, Driven by Transaction Growth DALLAS, July 31, 2024 /PRNewswire/ -- Wingstop Inc. (NASDAQ: WING) today announced financial results for the fiscal second quarter ended June 29, 2024. Highlights for the fiscal second quarter 2024 compared to the fiscal second quarter 2023: System-wide sales increased 45.2% to $1.2 billion 73 net new openings in the fiscal second quarter 2024 Domestic restaurant AUV increased to $2.0 million Domestic same st ...

Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (NASDAQ:PWUP), a Nasdaq Global Market® listed special purpose acquisition company ("PowerUp"), today announced that they have signed a non-binding letter of intent ("LOI") for a potential business combination ("Business Combination"). Under the terms of the LOI, followin ...

DALLAS, July 31, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced continuing progress in the development of DeepView SnapShot® M, a handheld diagnostic tool targeted for use in battlefield burn assessment that is based on the Company's AI-driven DeepView™ System platform. Burn wounds account for a significant portion ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. ("OLAPLEX"), today announced their participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. Amanda Baldwin, Chief Executive Officer will present on Wednesday, August 14, 2024 at 10:00am ET, and will meet with investors during the conference. The audio portion of the presentation will be available on the Company's Investor Relations website, https://ir.olaplex.com/, and will remain there for 90 days following the ev ...